CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

USANA Health Sciences Q3 sales fall 4%, cuts full year outlook

By Reuters News


Overview

  • Nutritional supplement maker's Q3 net sales fell 4% yr/yr on lower Core and Rise sales

  • Company posted Q3 net loss of $5.6 mln

  • Hiya active subscribers rose 18% sequentially; Core Nutritional margin expanded despite lower sales


Outlook

  • Company lowers 2026 consolidated net sales outlook to approaching $900 mln from $910 mln

  • Company cuts 2026 adjusted EBITDA forecast to $77 mln from $80.5 mln

  • Company says lower outlook reflects reduced Rise Wellness expectations and increased investment in Hiya


Result Drivers

  • HIYA MARKETING SPEND - Co increased marketing at Hiya, boosting active subscribers 18% sequentially but weighing on margins

  • LEANER COST STRUCTURE - Core Nutritional margin expanded due to leaner cost structure despite lower net sales

  • ACTIVE CUSTOMER INITIATIVES - Co said initiatives in Southeast Asia Pacific helped drive 3% sequential growth in active customers


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

$206 mln

$218.09 mln (1 Analyst)

Q3 Loss Per Share

$0.30

Q3 Net Earnings

-$5.6 mln


Analyst Coverage

  • Wall Street's median 12-month price target for USANA Health Sciences Inc is $25.00, about 69.8% above its November 2 closing price of $14.72

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Nov 2 - Herbalife's Q3 results beat estimates on Asia-Pacific sales growth; lifts FY outlook

  • Nov 3 - Vital Farms Q3 revenue misses estimates; cuts FY forecast

  • Nov 2 - Gaia Q3 revenue falls 12% but beats analyst expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.